<?xml version="1.0" encoding="UTF-8"?>
<results title="sars_covid_2">
 <result pre="(2019-nCoV) originating in Wuhan, China presents a potential respiratory viral" exact="pandemic" post="to the world population. Current efforts are focused on"/>
 <result pre="and widely available in the coming months to year(s). coronavirus" exact="Wuhan" post="neutralizing antibody ACE2 outbreak 2019-nCoV Funding The author(s) declared"/>
 <result pre="2 and Middle East Respiratory Syndrome (MERS) 3 are members." exact="SARS" post="and MERS famously caused their own outbreak concerns when"/>
 <result pre="caused their own outbreak concerns when they were originally identified." exact="SARS" post="caused significant economic damage to Hong Kong and Southern"/>
 <result pre="Kong and Southern China, before spreading to other countries. Ultimately," exact="SARS" post="infected up to 8,098 people and caused 774 deaths"/>
 <result pre="is now quickly spreading across the world after originating in" exact="Wuhan" post="1 . Human-to-human transmission of 2019-nCoV has been confirmed"/>
 <result pre="across the world after originating in Wuhan 1 . Human-to-human" exact="transmission" post="of 2019-nCoV has been confirmed in familial case cluster"/>
 <result pre="CT scan imaging 6 . Within China, the city of" exact="Wuhan" post="along with several others has been shut down, with"/>
 <result pre="for fever (≥38°C) and reported recent history of travel to" exact="Wuhan" post="in order to triage diagnostic testing 7 . These"/>
 <result pre="7 . These efforts resemble not only what happened with" exact="SARS" post="in 2002–2003, but also the Ebola virus outbreak in"/>
 <result pre="outbreaks 9 . There were no specific, antiviral treatments for" exact="SARS" post="or Ebola at the time of the outbreaks beyond"/>
 <result pre="immunogenic this particular protein will be beyond surrogate comparisons to" exact="SARS" post="and MERS, which limits the potential ability to quickly"/>
 <result pre="fusion is mediated at the cell membrane, delivering the viral" exact="nucleocapsid" post="inside the cell for subsequent replication 14 . The"/>
 <result pre="that the S protein does not function in just the" exact="virion" post="state alone. A neutralizing antibody targeting the S protein"/>
 <result pre="coverage is obtained with the neutralizing antibody. Information from other" exact="coronaviruses" post="species like SARS would be helpful as to where"/>
 <result pre="with the neutralizing antibody. Information from other coronaviruses species like" exact="SARS" post="would be helpful as to where to target the"/>
 <result pre="each animal 21 . Moreover, there is also the human" exact="immune response" post="against foreign immunoglobulins to other species, which would potentially"/>
 <result pre="One could look at genome homology of 2019-nCoV to the" exact="SARS" post="virus for comparison of conserved sequences, but this would"/>
 <result pre="efficacy against 2019-nCoV, similar to prior studies using them against" exact="SARS" post="32 . Research should continue to be undertaken to"/>
 <result pre="For further information, reviews of previous drug repurposing efforts for" exact="coronaviruses" post="are provided 34, 35 . Though these repurposed medications"/>
 <result pre="Patients with resolved viral infection will develop a polyclonal antibody" exact="immune response" post="to different viral antigens of 2019-nCoV. Some of these"/>
 <result pre="could be undertaken as was explored to treat the Ebola" exact="pandemic" post="40 , but would add complexity to the manufacturing"/>
 <result pre="uses the angiotensin-converting enzyme 2 (ACE2) as a receptor for" exact="cell entry" post="41 , which is the same receptor that the"/>
 <result pre="entry 41 , which is the same receptor that the" exact="SARS" post="coronavirus uses for entry 42 . For both viruses,"/>
 <result pre="protein on the virion, where after fusion of the viral" exact="membrane" post="and cell membrane will occur. Subsequently, the RNA virus"/>
 <result pre="virion, where after fusion of the viral membrane and cell" exact="membrane" post="will occur. Subsequently, the RNA virus will replicate its"/>
 <result pre="replicate its genome inside the cell, and ultimately make new" exact="virions" post="that will be secreted to infect other cells. The"/>
 <result pre="will be secreted to infect other cells. The coincidence of" exact="SARS" post="and 2019-nCoV using ACE2 receptor opens up the possibility"/>
 <result pre="up the possibility of using the extensive research studied on" exact="SARS" post="entry and applying it to 2019-nCoV. Based on the"/>
 <result pre="SARS entry and applying it to 2019-nCoV. Based on the" exact="SARS" post="literature, several potential blocking strategies could be considered, which"/>
 <result pre="which were shown to be effective in preventing infection in" exact="SARS" post="models. Blocking agents that bind to ACE2 receptor The"/>
 <result pre="first is using the small receptor-binding domain (RBD) from the" exact="SARS" post="S protein that has been shown to be the"/>
 <result pre="size, has been shown to effectively block the entry of" exact="SARS" post="in cell culture 44 . It is well within"/>
 <result pre="cell culture 44 . It is well within reason that" exact="SARS" post="RBD could be given to patients, thereby binding their"/>
 <result pre="and used as a therapy as well. This strategy assumes" exact="SARS" post="and 2019-nCoV share the same binding site on ACE2,"/>
 <result pre="is highly likely given the similar ACE2 binding sites of" exact="SARS" post="and NL63 coronavirus The small size of the therapy,"/>
 <result pre="likely given the similar ACE2 binding sites of SARS and" exact="NL63" post="coronavirus The small size of the therapy, similar in"/>
 <result pre="infection toward cell receptors, as well as to stimulate an" exact="immune response" post="against that specific viral domain in mice 47 ."/>
 <result pre="the coronavirus binds to ACE2 on infected cells, leading to" exact="cell entry." post="Three proposed strategies would block this interaction would abrogate"/>
 <result pre="first, the receptor-binding domain (RBD) of the spike protein from" exact="SARS" post="or 2019-nCoV would be administered, thereby binding ACE2 and"/>
 <result pre="accomplish the same. A third strategy would target the coronavirus" exact="virions" post="directly by using the ACE2 extracellular domain as bait"/>
 <result pre="( Figure 1). This strategy was shown to effectively block" exact="SARS" post="entry and replication in experiments 42 . While no"/>
 <result pre="There are several limitations to these two options. Regarding the" exact="SARS" post="RBD strategy, the body would likely develop an immune"/>
 <result pre="the SARS RBD strategy, the body would likely develop an" exact="immune response" post="to the SARS protein eventually, although the key intervention"/>
 <result pre="the body would likely develop an immune response to the" exact="SARS" post="protein eventually, although the key intervention period of infection"/>
 <result pre="would fall under this window of time, where after an" exact="immune response" post="for both viruses would develop. Alternatively, if one were"/>
 <result pre="were to use the homologous RBD from 2019-nCoV itself, this" exact="immune response" post="would likely be very advantageous since it could yield"/>
 <result pre="clinical symptoms. A study found that a fusion protein of" exact="SARS" post="RBD to Fc domain bound ACE2 in murine lung"/>
 <result pre="the virus ( Figure 1). Again, the research on the" exact="SARS" post="virus suggests this strategy is potentially promising. Soluble ACE2"/>
 <result pre="potentially promising. Soluble ACE2 receptor was demonstrated to block the" exact="SARS" post="virus from infecting cells in culture 42 . The"/>
 <result pre="42 . The reported affinity of soluble ACE2 for the" exact="SARS" post="S protein was 1.70 nM, which is comparable to"/>
 <result pre="to the human IgG1 domain (ACE2-NN-Ig) was effective in neutralizing" exact="SARS" post="coronavirus in vitro, with a 50% inhibitory concentration of"/>
 <result pre="directly treat the pneumonia pathophysiology. A portion of patients with" exact="SARS" post="and 2019-nCoV infection develop pneumonia, which is characterized by"/>
 <result pre="amino acids 18 – 615 appear to be sufficient for" exact="SARS" post="S protein binding 62 , which also covers the"/>
 <result pre="assume that the same ACE2 protein domains utilized by the" exact="SARS" post="virus are also bound by 2019-nCoV to infect cells."/>
 <result pre="cells. This may facilitate faster activation of the host antiviral" exact="immune response" post="and elimination of the virus, which was illustrated in"/>
 <result pre="and elimination of the virus, which was illustrated in a" exact="SARS" post="mouse model where Fc engaging antibodies were more potent"/>
 <result pre="model where Fc engaging antibodies were more potent in eliminating" exact="SARS" post="via activation of phagocytic cells compared to antibodies that"/>
 <result pre="neutralization, given the same protein is also its receptor for" exact="cell entry." post="Indeed, it has been shown that the pathogenicity of"/>
 <result pre="for cell entry. Indeed, it has been shown that the" exact="pathogenicity" post="of SARS versus the more mild human coronavirus NL63"/>
 <result pre="entry. Indeed, it has been shown that the pathogenicity of" exact="SARS" post="versus the more mild human coronavirus NL63 was related"/>
 <result pre="the pathogenicity of SARS versus the more mild human coronavirus" exact="NL63" post="was related to a lower affinity of NL63 for"/>
 <result pre="human coronavirus NL63 was related to a lower affinity of" exact="NL63" post="for human ACE2 versus SARS, with NL63 S protein"/>
 <result pre="lower affinity of NL63 for human ACE2 versus SARS, with" exact="NL63" post="S protein reducing ACE2 levels less than SARS S"/>
 <result pre="SARS, with NL63 S protein reducing ACE2 levels less than" exact="SARS" post="S protein 65 . Therefore, if 2019-nCoV were to"/>
 <result pre="a less pathogenic virus. This is similar to the re-emergent" exact="SARS" post="virus in 2003-2004, which had lower affinity for human"/>
 <result pre="ACE2 and resulted in less severe infection and no secondary" exact="transmission" post="66 . Thus, 2019-nCoV could be presented with an"/>
 <result pre="function of this sequence, while retaining high affinity binding for" exact="SARS" post="and 2019-nCoV S protein. Indeed, this possibility was previously"/>
 <result pre="domain abolished peptidase activity, but retained high affinity binding to" exact="SARS" post="S protein 56 . Of course, ACE2 peptidase mutation"/>
 <result pre="would likely become less pathogenic, similar to the comparison of" exact="SARS" post="versus human coronavirus NL63 65 . Lastly, scaling the"/>
 <result pre="pathogenic, similar to the comparison of SARS versus human coronavirus" exact="NL63" post="65 . Lastly, scaling the dose of any effective"/>
 <result pre="used as a therapeutic drug stockpile for future outbreaks of" exact="SARS" post="and 2019-nCoV, and any new coronavirus that emerges from"/>
 <result pre="the future that uses the ACE2 receptor for entry. Moreover," exact="coronaviruses" post="that replicate in animals across China and other countries"/>
 <result pre="predict a receptor that could be utilized in any zoonotic" exact="transmission" post="event, and build a new receptor immunoadhesin molecule in"/>
 <result pre=": Preparedness and proactive infection control measures against the emerging" exact="Wuhan" post="coronavirus pneumonia in China. J Hosp Infect. 2020; pii:"/>
 <result pre="Derkach P Swan S : Clinical course and management of" exact="SARS" post="in health care workers in Toronto: a case series."/>
 <result pre="antibodies against highly conserved HR1 and HR2 domains of the" exact="SARS-CoV" post="spike protein are more broadly neutralizing. PLoS One. 2012;"/>
 <result pre="al. : Repurposing of clinically developed drugs for treatment of" exact="Middle East respiratory syndrome" post="coronavirus infection. Antimicrob Agents Chemother. 2014; 58( 8): 4885–"/>
 <result pre=": Angiotensin-converting enzyme 2 is a functional receptor for the" exact="SARS" post="coronavirus. Nature. 2003; 426( 6965): 450– 454. 10.1038/nature02145 14647384"/>
 <result pre="MJ et al. : A 193-amino acid fragment of the" exact="SARS" post="coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J"/>
 <result pre="Ma C et al. : A truncated receptor-binding domain of" exact="MERS-CoV" post="spike protein potently inhibits MERS-CoV infection and induces strong"/>
 <result pre="A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits" exact="MERS-CoV" post="infection and induces strong neutralizing antibody responses: implication for"/>
 <result pre="Zhou Y Liu S et al. : Receptor-binding domain of" exact="SARS-CoV" post="spike protein induces highly potent neutralizing antibodies: implication for"/>
 <result pre="Y Rao S et al. : A crucial role of" exact="angiotensin converting enzyme 2" post="(ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;"/>
 <result pre="A crucial role of angiotensin converting enzyme 2 (ACE2) in" exact="SARS" post="coronavirus-induced lung injury. Nat Med. 2005; 11( 8): 875–"/>
 <result pre="F Li W Farzan M et al. : Structure of" exact="SARS" post="coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;"/>
 <result pre=": Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected" exact="SARS" post="coronavirus. Virology. 2014; 454–455: 157– 168. 10.1016/j.virol.2014.02.005 24725942 65"/>
</results>
